2.3—Small Molecule Antifungals Against Valley Fever

A groundbreaking new class of small-molecule antifungal drugs has been developed to address urgent global health challenges. These compounds show strong potential in treating a range of serious infections, including: hospital-acquired fungal infections, fungal infections in immunocompromised patients and drug-resistant pathogenic fungi. In preclinical studies, this novel drug class demonstrated efficacy in treating Coccidioidomycosis (Valley Fever) in a mouse model—an important validation of its therapeutic potential. As climate change accelerates the spread and virulence of fungal pathogens, the need for innovative antifungal solutions is more urgent than ever.

Inventor: Maciej Walczak (CU Boulder Chemistry)

Potential Applications: Health and Wellness, Therapeutics